JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
Toshihiko Wakabayashi(Nagoya University), Soichiro Shibui(Teikyo University Hospital), Takayuki Matsuo(Nagasaki University), Eiichi Ishikawa(Kyushu University), Hikaru Sasaki(Tokyo Dental College Ichikawa General Hospital), Takashi Maruyama(FIND), Ryo Nishikawa(Kanazawa Hospital), Akitake Mukasa(Kumamoto University Hospital), Haruhiko Fukuda(National Cancer Center Hospital East), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Akira Matsumura(Orihara Industrial (Japan)), Junki Mizusawa(Japan Clinical Cancer Research Organization), Tomokazu Aoki(Kitano Hospital), Yoko Nakasu(Miyoshi Kasei (Japan)), Yoshihiro Muragaki(Tokyo Women's Medical University), Kenichiro Asano(Hirosaki University), Yoshiki Arakawa(Kyoto Prefectural University of Medicine), Koji Yoshimoto(Kyushu University), Nobusada Shinoura(Tokyo Metropolitan Komagome Hospital), Shinya Sato(Tokuyama (Japan)), Kazuhiko Mishima, Akio Asai(Kansai Medical University), Fumiyuki Yamasaki(Hiroshima University), Kazuhiko Sugiyama(Hiroshima University), Atsushi Natsume(Nagoya Future Culture College), Motoo Nagane(Kyorin University), Mizuhiko Terasaki(Miyoshi Kasei (Japan)), Yasuo Iwadate(Miyoshi Kasei (Japan)), Yoshitaka Narita(Unknown), Toshihiro Kumabe(Kitasato University), Tamio Ito(Nakamura Memorial Hospital), Tatsuya Abe(Oita University), Hiroyuki Kobayashi(Juntendo University Hospital), Hirofumi Hirano(Kagoshima University), Takanori Onishi(Ehime University), Naoya Hashimoto(The University of Osaka), Takaaki Beppu(Iwate Medical University), Hideo Nakamura(Kurume University), Takamasa Kayama(Yamagata University), Atsuo Yoshino(Nihon University), Kaoru Kurisu(Chugoku Rosai Hospital), Hiroshi Katayama(National Cancer Center)
Cited by 65
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k